Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-01-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion from Huatai United Securities regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It references regulatory approvals, share issuance details, lock-up periods, shareholder commitments, and compliance with securities laws. The document is not a full financial report but a regulatory compliance and verification statement related to share circulation post-IPO. It is relatively short (3078 characters) and serves as a formal opinion or announcement rather than a detailed financial or management report. This fits best with the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-01-05 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining 25 medical device registration certificates. It details the product registration information, the impact on the company, and risk warnings. There is no financial data, no mention of financial results, no management discussion of financial performance, no voting results, no legal proceedings, no capital changes, and no executive changes. The document is a regulatory announcement about product certification and its business impact. It is not a report, transcript, or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-07 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露医疗器械注册证相关内容变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. regarding voluntary disclosure of changes related to medical device registration certificates. It details specific changes in the applicable models for various medical diagnostic reagent products, issued by the Jiangsu Provincial Drug Administration. The document is a regulatory announcement about product registration changes and does not contain financial data, earnings, management changes, or voting results. It is not a report or financial statement but a regulatory disclosure about product registration updates. Therefore, it fits best under Regulatory Filings (RNS). The document length is 6846 characters, which is sufficient for a detailed announcement but does not constitute a full report.
2021-12-07 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露全资下属公司获得医疗机构执业许可证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the voluntary disclosure that its wholly-owned subsidiary has obtained a medical institution practice license. The content focuses on the license details, the subsidiary's business plans, and risk warnings. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no legal proceedings, or other report types. The document is relatively short (987 characters) and serves as a regulatory announcement about a business development event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-29 Chinese
江苏浩欧博生物医药股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and management discussion about the quarter ending September 30, 2021. The report is unaudited as indicated. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. 9M 2021
2021-10-20 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司2021年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021年半年度持续督导跟踪报告" which translates to "2021 Semi-Annual Continuous Supervision Tracking Report". It is issued by the sponsor institution (华泰联合证券有限责任公司) responsible for continuous supervision of 江苏浩欧博生物医药股份有限公司 after its IPO on the STAR Market. The content includes detailed supervisory activities, review of information disclosure, risk factors, financial data for the first half of 2021, R&D progress, and use of raised funds. The document contains substantive financial data and analysis for the half-year period (2021 1-6 months), including income, profit, cash flow, and net assets, as well as detailed operational and risk disclosures. This matches the characteristics of an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K) or just an announcement. It is not a simple announcement or certification but a comprehensive report with financial and operational details for a period shorter than a full fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2021
2021-08-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.